Moonlighttx
Founded 2017 · 8 employees on LinkedIn · 2 known investors
Moonlight Therapeutics is a clinical-stage biotech company developing an intradermal stamp-based immunotherapy for people with food allergies. Its lead therapy, MOON101, targets peanut allergy.
Investors · 2
Competitors · 4
by search overlap
Maplightrx6 shared keywordsMapLight develops neurological and neuropsychiatric drug therapies using a discovery platform that identifies neural circuits linked to disease for targeted treatment of conditions like schizophrenia, Alzheimer's disease psychosis, and autism spectrum disorder.
Luminary Therapeutics5 shared keywords
Quiverquant4 shared keywordsQuiver Quantitative scrapes and aggregates alternative stock market data from across the internet into a free web dashboard. It targets retail investors, giving non-professional traders access to alternative data typically reserved for institutional money managers.
Werewolf Therapeutics3 shared keywordsWerewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer. The company focuses on leveraging immune modulation and innovative therapeutic approaches in oncology.
Companies competing with Moonlighttx for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $299.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2021 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2019 | $651.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Moonlighttx do?
- Moonlight Therapeutics is a clinical-stage biotech company developing an intradermal stamp-based immunotherapy for people with food allergies. Its lead therapy, MOON101, targets peanut allergy.
- Who are Moonlighttx's investors?
- Moonlighttx's investors include Allerfund Ventures, Llc, Portal Innovations.